Edibles and other infused product news and data. All cannabinoids.
Canadian marijuana operator Organigram Holdings is asking a federal court to quash a Health Canada decision that the company’s popular ingestible cannabis lozenges should be classified and regulated as edibles instead of extracts.
United Kingdom-based CBD and wellness brand Naturecan acquired the IAH Oregon cannabidiol production facility in the U.S. for 8 million pounds (roughly $10 million).
The CEO of Canadian producer Organigram Holdings is warning about heavily discounted marijuana in the nation’s recreational market, saying that ultra-low prices are “not sustainable and (hurt) the cannabis industry.”
New information and research about minor cannabinoids – among the 100-200 that have been identified – is helping treat different health and wellness conditions and allowing cannabis companies to sell a wider variety of products.
Potency testing on store-bought cannabis flower by a Canadian laboratory has found THC levels significantly lower than the labeled value, sparking an industrywide conversation about how to address inaccurate THC claims.
Another Canadian cannabis producer has hit pause on the production of certain products because of a dispute with Health Canada over what constitutes a cannabis “edible.”
A recent ruling from the U.S. Drug Enforcement Administration classifying a synthetic cannabinoid as a Schedule 1 drug has furthered the ire between the licensed cannabis industry and the largely unregulated cannabinoid sector, which has grown into a multi-billion market amid the proliferation of CBD and Delta-lineage products since the passage of the 2018 Farm Bill.
